Abstract 4128
Background
E-health incorporates a range of standards, tools and activities that use electronic to deliver information, resources and services in relation to health care. Final goal is improve quality of health information, strengthening national health systems and ensuring accessible health for population with reduce costs.
Imuno-oncology uses the power of the body’s own immune system to prevent, target, control, and eliminate cancer. Most of Immune related Adverse Events are moderate, reversible if detected early and properly. Teleoncology can decrease the existing gaps between care provider and patients. Allow patients to contact with professionals, permit communication, emotional support, regular assessment and, patient empowerment during and after treatment which rise patient adherence.
Methods
Describe the use of e-health systems to promote cancer care. How e-health technology can improve cancer nurse practise and empower cancer patients receiving Immunotherapy? 3 phases: first literature review searching for e-health nurses interventions with cancer patients in last years. Second; to recruit nurses’ priorities in the 2 countries (Portugal, Spain) to assess and control adherence. Finally a multimodal pathway using e-health technology to provide a checklist for professionals will be develop.
Results
The intended results are to provide a standardized system in order to facilitate the use of e-health, for cancer patients and professionals. Display evidence-based models using a process for framing a question, locating, assessing, evaluating, and repeating it as needed. Is projected to recognize professionals needed skills to improve e-Health technologies to support cancer care, specify e-health interventions for the management of immunotherapy side effects and factors that users perceive or experience as facilitators or barriers to the uptake and implementation of eHealth technologies.
Conclusions
Technology-based interventions could be suitable for immunotherapy treatment. The study will recognize the necessary skills and e-health best system to improve nursing care, adherence and promote quality of life. Further research is required to fully assess the impact of technology as an information and support mechanism for carers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract